LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis

Chen, Ningheng; Yin, Dengke; Lun, Bing; Guo, Xingyi

doi:10.1042/bsr20181440

Cited by 22 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the same families of genes discovered to be the target of several microRNAs we mention CXCL-12/16 [16,86], CCNG-1/2 [17,100], IRS-1/2 [19,107], FGF-2/FR [28,112], CCDC-6/67 [52,128], FOX-O1/E1/M1 [27,55,76], ITGA-3/6 [55,61], SL-1A5/25A1 [56,118], MAP-2K4/K1/4K3 [71,78,120], and SOX 11/12/2 [84,95,117].…”

Section: One Gene Can Be Targeted By Several Micrornasmentioning

confidence: 99%

MicroRNA in Papillary Thyroid Carcinoma: A Systematic Review from 2018 to June 2020

Hîțu

Gabora

Bonci

et al. 2020

Cancers

View full text Add to dashboard Cite

The involvement of micro-ribonucleic acid (microRNAs) in metabolic pathways such as regulation, signal transduction, cell maintenance, and differentiation make them possible biomarkers and therapeutic targets. The purpose of this review is to summarize the information published in the last two and a half years about the involvement of microRNAs in papillary thyroid carcinoma (PTC). Another goal is to understand the perspective offered by the new findings. Main microRNA features such as origin, regulation, targeted genes, and metabolic pathways will be presented in this paper. We interrogated the PubMed database using several keywords: “microRNA” + “thyroid” + “papillary” + “carcinoma”. After applying search filters and inclusion criteria, a selection of 137 articles published between January 2018–June 2020 was made. Data regarding microRNA, metabolic pathways, gene/protein, and study utility were selected and included in the table and later discussed regarding the matter at hand. We found that most microRNAs regularly expressed in the normal thyroid gland are downregulated in PTC, indicating an important tumor-suppressor action by those microRNAs. Moreover, we showed that one gene can be targeted by several microRNAs and have nominally described these interactions. We have revealed which microRNAs can target several genes at once.

show abstract

Section: One Gene Can Be Targeted By Several Micrornasmentioning

confidence: 99%

MicroRNA in Papillary Thyroid Carcinoma: A Systematic Review from 2018 to June 2020

Hîțu

Gabora

Bonci

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…The differential expressions of those lncRNAs have also been found to be cells, tissue, and plasma in the TC. As discussed earlier, some lncRNAs, such as CCAT1, H19, HCP5, HOTTIP, , MALAT1, HOXA-AS2, SNHG15, SPRY4-IT, and UCA1, have been found to be upregulated in TC (7,23,25,26,30,42,70,111,112), whereas others, such as BANCR, AB074169, ASMTL-AS1, BLACAT1, CASC2, HOTAIRM1, GAS5, PAR5, SNHG3, GAS8-AS1, and MEG3 are downregulated (38)(39)(40)(43)(44)(45)47,104,108,112,113). This unique biologic behavior exhibited by different groups of lncRNAs shows value for the prognostic and diagnostic determination in TC patients.…”

Section: Lncrnas As Diagnostic and Prognostic Markers In Tcmentioning

confidence: 74%

“…Chen et al found that the GAS8-AS1 was downregulated in PTC cell lines and suppressed the cell proliferation and cycle of PTC cells. Further studies showed that GAS8-AS1 regulates a downstream target of miR-135b-5p, cyclin G2, whereas overexpressed GAS8-AS1 inhibits tumor formation and suppresses PTC cell growth (108). These studies demonstrate that GAS8-AS1 inhibits PTC cell growth via the miR-135b-5p/CCND2 axis, and acts as a tumor suppressor gene in PTC.…”

Section: Gas8-as1mentioning

confidence: 76%

Long non-coding RNA signatures as predictors of prognosis in thyroid cancer: a narrative review

Zhao¹,

Souza²,

Kumar³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Thyroid cancer (TC) is the most common endocrine malignancy, with high incidence rates in recent decades. Most TC cases have good prognoses, but a high risk of recurrence and metastases poses challenges, especially for patients with high-risk factors. Currently used prognostic markers for TC involve a combination of genetic factors and overexpressed proteins. Long non-coding RNAs (lncRNAs) regulate several integral biologic processes by playing key roles in the transcription of several downstream targets maintaining cellular behavior. Prior studies have revealed that lncRNAs promote tumor cell proliferation, invasion, metastasis, and angiogenesis, making them important targets for therapeutic intervention in cancer.While the exact molecular mechanisms underlying the role of lncRNAs in modulating TC progression and recurrence is still unclear, it is important to note that some lncRNAs are upregulated in certain cancers, while others are downregulated. In the present study, we review several key lncRNAs, their association with cancer progression, and the important roles they may play as tumor suppressors or tumor promoters in tumorigenesis. We discuss the potential mechanisms of lncRNA-mediated pathogenesis that can be targeted for the treatment of TC, the existing and potential benefits of using lncRNAs as diagnostic and prognostic measures for cancer detection, and tumor burden in patients.

show abstract

“…And then MLK7-AS1 upregulated the expression of Yes related protein 1, promoted the proliferation and development of OC, and was associated with the survival and prognosis of OC patients. 10 It has been reported that GAS8-AS1 contributed to the development of colorectal cancer, 11 papillary thyroid carcinoma 12 and hepatocellular carcinoma. 13 However, the function of GAS8-AS1 in ovarian cancer is poorly defined.…”

Section: Introductionmentioning

confidence: 99%

<p>LncRNA GAS8-AS1 Inhibits Ovarian Cancer Progression Through Activating Beclin1-Mediated Autophagy</p>

Fang¹,

Ping²,

Zhai³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Early detection and diagnosis of ovarian cancer (OC) is complicated due to the concealment of the ovarian anatomical position and the lack of clinical manifestations and specific indicators of early OC. Therefore, it is urgent to study the pathogenesis of OC, especially the molecular mechanism. Results: LncRNA GAS8-AS1 was decreased in OC tissues and cell lines, and high expression of GAS8-AS1 indicated a higher 5-year survival rate of OC patients. Overexpression of GAS8-AS1 suppressed growth of OC cells, while deletion of GAS8-AS1 promoted the progression of OC cells. Further data indicated GAS8-AS1 activated autophagy in OC cells. Functional experiments showed that 3-MA removed the inhibitory effect of GAS8-AS1 in OC cells. On the contrary, Rapamycin reversed the promoting effect of GAS8-AS1 in OC cells. Furthermore, GAS8-AS1 bound with Beclin1 and promoted its expression, and silencing of Beclin1 reversed the inhibitory role of GAS8-AS1 in OC progression. In vivo tumorigenesis assay showed GAS8-AS1 suppressed OC progression and activated Beclin1 mediated autophagy. Conclusion: Our study suggested GAS8-AS1 inhibited OC progression by activating autophagy via binding with Beclin1, and GAS8-AS1 might be a potential therapeutic target for OC clinical treatment.

show abstract

LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis

Cited by 22 publications

References 35 publications

MicroRNA in Papillary Thyroid Carcinoma: A Systematic Review from 2018 to June 2020

MicroRNA in Papillary Thyroid Carcinoma: A Systematic Review from 2018 to June 2020

Long non-coding RNA signatures as predictors of prognosis in thyroid cancer: a narrative review

<p>LncRNA GAS8-AS1 Inhibits Ovarian Cancer Progression Through Activating Beclin1-Mediated Autophagy</p>

Contact Info

Product

Resources

About